Noticias de Eulerpool Shin Nippon Biomedical Laboratories

Shin Nippon Biomedical Laboratories Noticias de Acciones

Shin Nippon Biomedical Laboratories es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Shin Nippon Biomedical Laboratories.

• 19 de junio ·

  Yahoo
  Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
• 1 de mayo ·

  Yahoo
  Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
• 28 de marzo ·

  Yahoo
  SNBL and Tasso, Inc. to Establish Joint Venture in Japan
• 31 de octubre ·

  Yahoo
  Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
• 8 de octubre ·

  Yahoo
  Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
• 13 de junio ·

  Yahoo
  Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting